August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.44. Operator: Good morning. My name is John, and I'll be your conference ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

Arvinas Holding Company recently held its earnings call, revealing a balanced sentiment among stakeholders. The company showcased strong clinical progress and significant collaborations, notably with ...